68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients

Caroli, Paola; Sandler, Israel; Matteucci, Federica; Giorgi, Ugo De; Uccelli, Licia; Celli, Monica; Foca, Flavia; Barone, Domenico; Romeo, Antonino; Sarnelli, Anna; Paganelli, Giovanni

doi:10.1007/s00259-018-4067-3

Cited by 82 publications

(54 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 5 out 8 articles with available information on PSAdt, an increase of the DR of PSMA‐PET in patients with PSAdt ≤6 months and a decrease of DR of PSMA‐PET in patients with PSAdt > 6 months were reported . Of the remaining 3 articles, one study showed an opposite trend and the other two a reduction or a raise of the DR irrespective of the value of the PSAdt. The possible correlation between the DR of PSMA‐PET and PSAvel was evaluated in seven studies .…”

Section: Resultsmentioning

confidence: 99%

“…After reviewing the full texts, four articles were excluded from the quantitative analysis (meta‐analysis) due to insufficient data to reassess the correlation between PSA kinetics and DR of PSMA‐PET and 8 studies including about 1,400 patients were finally selected for the meta‐analysis (Figure ).…”

Section: Resultsmentioning

confidence: 99%

“…After reviewing the full texts, four articles were excluded from the quantitative analysis (meta-analysis) due to insufficient data to reassess the correlation between PSA kinetics and DR of PSMA-PET 22,24,26,29 and 8 studies including about 1,400 patients were finally selected for the meta-analysis 20,21,23,25,27,28,30,31 (Figure 1). Table 1 summarizes the characteristic of the articles correlating PSMA-PET findings and PSA kinetics selected for the systematic review (Table 1).…”

Section: T a B L E 3 Correlation Between Detection Rate Of Psma-pet Amentioning

confidence: 99%

“…Eight out twelve studies, including about 1400 patients with BRPCa, were selected for the meta-analysis. 20,21,23,25,27,28,30,31 Sufficient data were available to calculate the pooled DR of PSMA-PET (Figure 3) and the pooled OR of a positive PSMA-PET ( Figure 4) in patients with PSAdt ≤6 months compared to those with PSAdt>6 months.…”

Section: Quantitative Analysis (Meta-analysis)mentioning

confidence: 99%

See 3 more Smart Citations

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Mestre

Treglia

Ferrari

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Serum prostate‐specific antigen (PSA) may predict the risk of positive positron emission tomography/computed tomography with radiolabelled prostate‐specific membrane antigen (PSMA‐PET/CT) in patients with biochemical recurrent prostate cancer (BRPCa). However, to date, there are no clear data regarding the correlation between PSA kinetics and PSMA‐PET findings. We performed a systematic review and meta‐analysis to provide evidence‐based data in this setting. Methods A comprehensive literature search of studies published through October 2018 in PubMed/MEDLINE, EMBASE and Cochrane library databases was performed. A meta‐analysis to establish the detection rate (DR) of PSMA‐PET using different cut‐off values of PSA doubling time (PSAdt) and a pooled analysis to establish whether shorter PSAdt may predict positive PSMA‐PET results was performed in patients with BRPCa. Results Twelve articles were included in the systematic review, and eight articles (including about 1400 patients) were selected for the meta‐analysis. The pooled DR including 95% confidence intervals (95%CI) of PSMA‐PET in restaging prostate cancer (PCa) patients was 72% (95%CI:60%‐82%), increasing to 83% (95%CI:75%‐90%) when PSAdt was ≤6 months and decreasing to 60% (95%CI:37%‐80%) when PSAdt was >6 months, without a statistical significant difference. PSAdt ≤6 months may predict the positive result of PSMA‐PET (pooled odds ratio: 3.22; 95%CI:1.17‐8.88). Statistical heterogeneity among the included studies was found. Conclusions PSA kinetics, and in particular shorter PSAdt, may be predictor of PSMA‐PET positivity in patients with BRPCa. Further larger studies in this setting are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: T a B L E 3 Correlation Between Detection Rate Of Psma-pet Amentioning

confidence: 99%

Section: Quantitative Analysis (Meta-analysis)mentioning

confidence: 99%

See 2 more Smart Citations

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Mestre

Treglia

Ferrari

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…PSMA PET/CT nowadays represents the molecular imaging with the highest accuracy in staging and restaging PCa patients . Several studies showed the better diagnostic performance of PSMA PET/CT as compared with other PET tracers and conventional imaging techniques (including CT, MRI and BS), even in the presence of low PSA levels . Of note, the conventional clinical practice in PCa patients with BCR after RP includes mainly three approaches (radiotherapy, ADT or observation), according to the presumed site of recurrence (local vs systemic) .…”

Section: Introductionmentioning

confidence: 99%

How does ⁶⁸Ga‐prostate‐specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?

et al. 2019

View full text Add to dashboard Cite

Objective: To evaluate the clinical impact of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery. Methods: We enrolled 276 prostate cancer patients referred to 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none. Results: The overall detection rate of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time <3 months (odds ratio 3.98) were independent predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography results (all P ≤ 0.03). 68 Ga-prostatespecific membrane antigen positron emission tomography/computed tomography led to a major treatment change in 177 cases (64.1%), with a minor clinical impact of 2.5%. The overall clinical impact of 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 42.4%, 27.7%, 21.2% and 8.7% in men with prostatespecific antigen at 68 Ga-prostate-specific membrane antigen positron emission tomography/ computed tomography of 0.2-0.4, 0.5-1, 1.1-2 and >2 ng/mL, respectively. Conclusions: 68 Ga-prostate-specific membrane antigen positron emission tomography/ computed tomography allows clinicians to radically change the intended treatment approach before imaging evaluation, in roughly two out three individuals. membrane antigen positron emission tomography/computed tomography, clinical impact, prostate cancer, recurrence, treatment plan change. 804

show abstract

Hot issues on Chinese expert consensus of prostate cancer management

Han,

Sheng,

Qin

et al. 2024

UroPrecision

View full text Add to dashboard Cite

Prostate cancer is one of the most common solid tumors in men, and its incidence continues to rise in China. Several guidelines have been developed and published to facilitate the standardization of diagnosis and treatment of prostate cancer. However, there are still many challenges and issues in clinical practice that lack high‐level evidence. A panel of recognized domestic experts including urologists, medical oncologists, and radiologists was organized and invited to discuss and vote on the key issues of lacking high‐level evidence and unified guideline recommendations questions. Following careful selection and voting processes, 19 questions were identified, leading to the establishment of a consensus based on collective agreement regarding these hot issues. The aim of this consensus is to provide a reference for managing the whole patient journey of prostate cancer for Chinese clinicians.

show abstract

68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients

Abstract: We confirmed the value of Ga-PSMA PET/CT in restaging PCa patients with BCR, highlighting its superior performance and safety compared with choline PET/CT. Higher PSApet was associated with a higher relapse detection rate.

Cited by 82 publications

References 45 publications

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

How does ⁶⁸Ga‐prostate‐specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?

Hot issues on Chinese expert consensus of prostate cancer management

Contact Info

Product

Resources

About

68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients

Abstract: We confirmed the value of Ga-PSMA PET/CT in restaging PCa patients with BCR, highlighting its superior performance and safety compared with choline PET/CT. Higher PSApet was associated with a higher relapse detection rate.

Cited by 82 publications

References 45 publications

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis

How does 68Ga‐prostate‐specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?

Hot issues on Chinese expert consensus of prostate cancer management

Contact Info

Product

Resources

About

How does ⁶⁸Ga‐prostate‐specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?